ZPBP2 and inflammatory bowel disease: In the ORMDL3-GSDMB-IKZF3-ZPBP2 locus, we observed that risk for IBD, UC, CD, RA, PBC, asthma, and levels of HDL cholesterol increased with increasing levels of afucosylated agalactosylated and monogalactosylated glycans (IGP2 and IGP6) and decreased with increasing levels of fucosylation for all diseases, except IBD and CD.